BACKGROUND: Accumulating evidence indicates that cells expressing Toll-like receptors (TLRs) play an important role in allergic diseases. The authors undertook this study to explore the hypothesis that TLR-mediated inflammatory signals are important from the perspective of asthma management. METHODS: The expressions of TLR1, TLR2, TLR3, TLR4, TLR6, and TLR9 and levels of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6, IL-8, and IFN-gamma) on the peripheral blood mononuclear cells (PBMCs) of 36 stable asthmatics on treatment (the on-treatment group), 15 asthmatics (the treatment-naïve group) before and after a 7-day course of oral prednisolone (30 mg/day), and on the PBMCs of 15 healthy controls were measured after in vitro stimulation using TLR-specific ligands. RESULTS: In the on-treatment group, TLR1, TLR2, TLR6, and TLR9 expressions on PBMCs were significantly different between asthmatics and controls. And the expression of TLR4 on PBMCs and TNF-alpha production stimulated by lipopolysaccharide (LPS), were significantly higher in mild to moderate than in severe asthmatics. Interestingly, in the treatment-naïve group, short-term prednisolone significantly increased LPS-induced TNF-alpha and IFN-gamma productions by PBMCs. CONCLUSION: TLR-mediated inflammatory signals contribute to the development and severity of asthma and are not reduced by glucocorticoid treatment, which suggests that a TLR-specific antagonist and glucocorticoid are required for the effective control of airway inflammation in asthmatics.
BACKGROUND: Accumulating evidence indicates that cells expressing Toll-like receptors (TLRs) play an important role in allergic diseases. The authors undertook this study to explore the hypothesis that TLR-mediated inflammatory signals are important from the perspective of asthma management. METHODS: The expressions of TLR1, TLR2, TLR3, TLR4, TLR6, and TLR9 and levels of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6, IL-8, and IFN-gamma) on the peripheral blood mononuclear cells (PBMCs) of 36 stable asthmatics on treatment (the on-treatment group), 15 asthmatics (the treatment-naïve group) before and after a 7-day course of oral prednisolone (30 mg/day), and on the PBMCs of 15 healthy controls were measured after in vitro stimulation using TLR-specific ligands. RESULTS: In the on-treatment group, TLR1, TLR2, TLR6, and TLR9 expressions on PBMCs were significantly different between asthmatics and controls. And the expression of TLR4 on PBMCs and TNF-alpha production stimulated by lipopolysaccharide (LPS), were significantly higher in mild to moderate than in severe asthmatics. Interestingly, in the treatment-naïve group, short-term prednisolone significantly increased LPS-induced TNF-alpha and IFN-gamma productions by PBMCs. CONCLUSION: TLR-mediated inflammatory signals contribute to the development and severity of asthma and are not reduced by glucocorticoid treatment, which suggests that a TLR-specific antagonist and glucocorticoid are required for the effective control of airway inflammation in asthmatics.
Authors: Ning Zhang; Quynh Ai Truong-Tran; Brian Tancowny; Kathleen E Harris; Robert P Schleimer Journal: J Immunol Date: 2007-07-01 Impact factor: 5.422
Authors: P G Woodruff; R Khashayar; S C Lazarus; S Janson; P Avila; H A Boushey; M Segal; J V Fahy Journal: J Allergy Clin Immunol Date: 2001-11 Impact factor: 10.793
Authors: Edward M Erin; Brian R Leaker; Grant C Nicholson; Andrew J Tan; Linda M Green; Helen Neighbour; Angela S Zacharasiewicz; Jackie Turner; Elliot S Barnathan; Onn Min Kon; Peter J Barnes; Trevor T Hansel Journal: Am J Respir Crit Care Med Date: 2006-07-13 Impact factor: 21.405
Authors: Ana Paula Moreira; Karen A Cavassani; Ugur B Ismailoglu; Rikki Hullinger; Michael P Dunleavy; Darryl A Knight; Steven L Kunkel; Satoshi Uematsu; Shizuo Akira; Cory M Hogaboam Journal: J Clin Invest Date: 2011-10-17 Impact factor: 14.808
Authors: Astrid Crespo-Lessmann; Eder Mateus; Silvia Vidal; David Ramos-Barbón; Montserrat Torrejón; Jordi Giner; Lorena Soto; Cándido Juárez; Vicente Plaza Journal: Respir Res Date: 2016-04-16
Authors: Seil Sagar; Kim A T Verheijden; Niki A Georgiou; Johan Garssen; Aletta D Kraneveld; Arjan P Vos; Gert Folkerts Journal: Mediators Inflamm Date: 2013-05-27 Impact factor: 4.711